Inclusion of Metabolic Tumor Volume in Prognostic Models of Bone and Soft Tissue Sarcoma Increases the Prognostic Value

Sarcomas are rare and have a high mortality rate. Further prognostic classification, with readily available parameters, is warranted, and several studies have examined circulating biomarkers and PET parameters separately. This single-site, retrospective study aimed to examine the prognostic values o...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2023-01, Vol.15 (3), p.816
Main Authors: Pedersen, Mette Abildgaard, Baad-Hansen, Thomas, Gormsen, Lars C, Bærentzen, Steen, Sandfeld-Paulsen, Birgitte, Aggerholm-Pedersen, Ninna, Vendelbo, Mikkel Holm
Format: Article
Language:English
Subjects:
Albumin
Biomarkers
Bone tumors
Cell metabolism
Health aspects
Hemoglobin
Lymphocytes
Medical imaging
Medical prognosis
Metabolism
Metastasis
Neutrophils
PET imaging
Physiological aspects
Prognosis
Sarcoma
Soft tissue sarcoma
Statistical analysis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sarcomas are rare and have a high mortality rate. Further prognostic classification, with readily available parameters, is warranted, and several studies have examined circulating biomarkers and PET parameters separately. This single-site, retrospective study aimed to examine the prognostic values of several scoring systems in combination with PET parameters. We included 148 patients with sarcoma, who were treated and scanned at Aarhus University Hospital from 1 January 2016 to 31 December 2019. The Akaike information criterion and Harrell's concordance index were used to evaluate whether the PET parameters added prognostic information to existing prognostic models using circulating biomarkers. Of the PET parameters, metabolic tumor volume (MTV) performed best, and when combined with the existing prognostic models, the prognostic value improved in all models. Backward stepwise selection was used to create a new model, SBSpib, which included albumin, lymphocytes, and one PET parameter, MTV. It has scores ranging from zero to three and increasing hazard ratios; HR = 4.83 (1.02-22.75) for group one, HR = 7.40 (1.6-33.42) for group two, and HR = 17.32 (3.45-86.93) for group three. Consequently, implementing PET parameters in prognostic models improved the prognostic value. SBSpib is a new prognostic model that includes both circulating biomarkers and PET parameters; however, validation in another sarcoma cohort is warranted.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15030816